Nivolumab

ClinicalJuly 31, 2026

Phase II Trial of Nivolumab and Ipilimumab in Kidney Transplant Recipients with Metastatic Skin Cancer

A phase II trial is underway testing nivolumab and ipilimumab combined with sirolimus and prednisone in kidney transplant recipients with unresectable or metastatic skin cancer.

Sponsor company

Mechanism of action

Recent signals(17)

Phase II Trial of Nivolumab and Cabozantinib for Mucosal Melanoma Recurrence Prevention

Phase II Trial of Nivolumab and Ipilimumab in Kidney Transplant Recipients with Metastatic Skin Cancer

Nivolumab Added to Standard Treatment in Advanced Stomach/Esophageal Cancer Trial

Phase I Trial of Lenalidomide and Nivolumab in Primary CNS Lymphoma

Phase II Trial of Nivolumab and Ipilimumab in dMMR Recurrent Endometrial Carcinoma

Corcept initiates study of nenocorilant with nivolumab in advanced solid tumors

Phase II/III Trial of Nivolumab and Ipilimumab for Advanced Melanoma Initiated

Study on Vidutolimod and Nivolumab in Melanoma Treatment

Phase Ib/II Trial of Ipilimumab, Nivolumab, and Nogapendekin Alfa in NSCLC

Phase II Trial of Nivolumab and Ipilimumab Before Surgery in Sarcomatoid Mesothelioma

Phase Ib Trial of Aldesleukin with Nivolumab for Gastric Cancer with Peritoneal Metastasis

Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

Phase II Trial of Nivolumab and Ipilimumab for Rare Tumors

Phase II Trial of Nivolumab for Persistent Cervical Cancer Shows Potential Efficacy

Nivolumab Phase III Trial for High Risk Stage II-IIIB Anal Cancer Initiated

Phase III Trial of Nivolumab Post-Surgery in Non-Small Cell Lung Cancer

Phase I/IIa Trial of MC1R-targeted Therapy with Nivolumab in Advanced Melanoma

Upcoming milestones

Related catalysts

Indications

Therapeutic areas

Get signals before the market moves